MTOR and breast cancer: Overactivation of FGFR3 reduces the sensitivity of ER+ BC to tamoxifen via Ras/Raf/MAPK kinase 1/2/extracellular signal-regulated kinase 1/2 and PI3K/AKT/mTOR signaling [119].